CORMEDIX INC. Revenue from Contract with Customer, Excluding Assessed Tax
CORMEDIX INC. (CRMD) reported Revenue from Contract with Customer, Excluding Assessed Tax of $101.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-13
- CORMEDIX INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $101.93M, a 156.52% increase year-over-year.
- CORMEDIX INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $127.43M, a 226.05% increase year-over-year.
- CORMEDIX INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $39.74M.
- CORMEDIX INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $39.08M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month |
|---|---|---|
| 2026-06-30 | $101.93M 10-Q · filed 2026-08-13 | $229.36M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $127.43M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $39.74M 10-Q · filed 2026-08-13 | $78.82M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $39.08M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |